Navigation Links
Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
Date:12/6/2007

SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company has closed its sale and leaseback agreement with Veralliance Properties for its real estate assets. Total consideration received by Neurocrine for the properties was $109 million. Concurrently with the closing of the transaction, Neurocrine leased back its corporate headquarters for a 12 year term, with renewal options. Neurocrine also has certain options under the lease to repurchase all of the properties included in the transaction at certain times during lease period. Under the terms of the asset purchase agreement, Neurocrine will receive cash of approximately $61 million net of fees, expenses and existing indebtedness.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, endometriosis, irritable bowel syndrome, pain, and diabetes. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general. Other risks are described in the Company's report on Form 10-K for the year ended December 31, 2006 and Form 10-Q for the quarter ended September 30, 2007. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... 29, 2017 , ... Phytomer USA is pleased to introduce Jennifer Smith as ... Smith’s role is to provide excellent customer service, support, training and knowledge to spa ... comes to Phytomer with a wealth of industry experience including roles as spa manager ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... (The National Campaign) announces its support for the Access to Contraception for ... Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ensure that ...
(Date:4/28/2017)... ... , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today ... outlook as “stable.” At the same time, the ratings agency cautioned that the company’s ... below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to ...
(Date:4/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... board election process has been in place since the RBMA was founded in 1968 ... FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... , April 19, 2017 The Global ... Forecast to 2022 report has covered and analysed the potential ... information on market size, shares and growth factors. The report ... challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major ...
Breaking Medicine Technology: